InspireMD, Inc. NSPR
As ofNov 20, 2026, 3:59 PM EST
- YTD
- -69.66%
- 1 year
- -68.24%
- Market cap
- 29.23M
- Revenue (ttm)
- 6.82M
- EPS (ttm)
- -0.57
- Shares out
- 26.08M
- Forward P/E
- -4.15
- YTD return
- -69.66%
- 1-year return
- -68.24%
- 50-day average
- 2.69
- Volume
- 590.77K
- Avg volume
- 226.08K
- Open
- 0.595
- Previous close
- 0.6205
- Day's range
- 0.4999 – 0.63
- 52-week range
- 0.44 – 2.15
- Analysts
- Strong Buy
- Price target
- 4.75 (+779.6%)
Key statistics
- 200-day average
- 2.57
- Enterprise value
- 37.44M
- Price / sales
- 11.28
- Price / book
- 1.83
- Revenue growth
- 16.30%
- Total cash
- 40.40M
- Total debt
- 682.00K
- Return on equity
- -66.75%
- Short % of float
- 0.90%
Fundamental scorecard
8 of 25 checks passed on NSPR’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.20 | -0.16 | +0.04 | +20.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.19 | -0.22 | -0.03 | -15.79% |
| May 14, 2024 | Mar 1, 2024 | -0.15 | -0.21 | -0.06 | -40.00% |
| Mar 6, 2024 | Dec 1, 2023 | -0.20 | -0.16 | +0.04 | +20.00% |
| Nov 6, 2023 | Sep 1, 2023 | -0.17 | -0.15 | +0.02 | +11.76% |
| Aug 8, 2023 | Jun 1, 2023 | -0.17 | -0.24 | -0.07 | -41.18% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Lake Street | init | — | Buy |
| Nov 2, 2023 | Piper Sandler | main | Overweight | Overweight |
| Jun 12, 2023 | Piper Sandler | init | — | Overweight |
| May 17, 2023 | National Alliance Securities | main | — | Buy |
| Mar 31, 2023 | Alliance Global Partners | main | — | Buy |
About InspireMD, Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Israel
- Website
- inspiremd.com
News
InspireMD, Inc. (NSPR) Discusses Carotid Artery Disease Management and CGuard Prime Clinical Benefits Transcript InspireMD Completes First U.S. Commercial Transcarotid Artery Revascularization Procedures Utilizing Its CGuard Prime TransCarotid Stent System
InspireMD Announces First U.S. Commercial TCAR Procedures Using the FDA-Approved CGuard® Prime TransCarotid Stent System
InspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD's CGuard Prime Carotid Stent Platform
InspireMD (NSPR) Upgraded to Buy: Here's Why
InspireMD Announces Talks Featuring CGuard and CGuard Prime at VEITHsymposium 2026
InspireMD Announces Pricing of $37.5 Million Public Offering
12 Health Care Stocks Moving In Friday's Pre-Market Session Update: InspireMD Q3 Adj. EPS $(0.11) Beats $(0.15) Estimate, Sales $2.242M Beat $1.996M Estimate
12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on NSPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARNOLD KATHRYN | Director | Stock Award(Grant) | Jan 22, 2024 | 215,040 |
| BERMAN MICHAEL | Director | Conversion of Exercise of derivative security | Jun 23, 2024 | 0 |
| GLEASON SHANE THOMAS | Officer | Stock Award(Grant) | Jan 22, 2024 | 514,365 |
| KESTER THOMAS J | Director | Conversion of Exercise of derivative security | May 27, 2024 | 326,652 |
| ROUBIN GARY S | Director | Conversion of Exercise of derivative security | May 27, 2024 | 501,788 |
| SHORE CRAIG | Chief Financial Officer | Stock Award(Grant) | Jan 22, 2024 | 879,844 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 9.64% | 2,514,046 | 7.42M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 8.47% | 2,209,593 | 6.52M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 8.18% | 2,133,405 | 6.29M | Sep 29, 2024 |
| Marshall Wace LLP | 7.13% | 1,860,405 | 5.49M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 5.28% | 1,378,128 | 4.07M | Sep 29, 2024 |
| Velan Capital Investment Management LP | 3.47% | 904,029 | 2.67M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.07% | 18,244 | 53.82K | Oct 30, 2024 |
